

## Half Year Results Investor Briefing

**Sydney, Australia, Wednesday, 26 August 2020:** Next Science Limited (ASX:NXS) provides its Half Year Report for the six months ended 30 June 2020.

Next Science's Managing Director, Judith Mitchell, will host an investor conference call and webcast at **10.30am** (AEST) on **26 August 2020** to discuss the results. The briefing is expected to last approximately 45 minutes inclusive of question time.

To pre-register for the call, please use the following link:

<https://s1.c-conf.com/diamondpass/10009073-invite.html>

To register to participate via webcast, please use the following link:

<https://webcast.openbriefing.com/6400/>

Approved and authorised by Judith Mitchell, Managing Director, Next Science Limited.

Further information:

Judith Mitchell  
Managing Director, Next Science Limited  
Phone: +61 2 9375 7989  
Email: [investorqueries@nextscience.com](mailto:investorqueries@nextscience.com)

Michael Brown  
Pegasus Advisory  
Phone: +61 400 248 080  
Email: [mbrown@pegasusadvisory.com.au](mailto:mbrown@pegasusadvisory.com.au)

## About Next Science

Next Science is a medical technology company headquartered in Sydney, Australia, with a research and development centre in Florida, USA. Established in 2012, the Company's primary focus is on the development and commercialisation of its proprietary Xbio™ technology to reduce the impact of biofilm based infections in human health. Xbio is a unique, non-toxic technology with proven efficacy in eradicating both biofilm based and free-floating bacteria. Next Science owns 100% of the patent protected intellectual property relating to its Xbio technology. Website: [www.nextscience.com](http://www.nextscience.com).